Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Jul;40(1):1–9. doi: 10.1111/j.1365-2125.1995.tb04527.x

Science, medicine and clinical pharmacology. The Lilly Lecture 1994.

A Breckenridge 1
PMCID: PMC1365020  PMID: 8527257

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry M., Howe J. L., Back D. J., Swart A. M., Breckenridge A. M., Weller I. V., Beeching N., Nye F. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. Br J Clin Pharmacol. 1994 Jan;37(1):7–12. doi: 10.1111/j.1365-2125.1994.tb04231.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barry M., Wild M., Veal G., Back D., Breckenridge A., Fox R., Beeching N., Nye F., Carey P., Timmins D. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS. 1994 Aug;8(8):F1–F5. doi: 10.1097/00002030-199408000-00002. [DOI] [PubMed] [Google Scholar]
  3. Clarke J. B., Neftel K., Kitteringham N. R., Park B. K. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int Arch Allergy Appl Immunol. 1991;95(4):369–375. doi: 10.1159/000235475. [DOI] [PubMed] [Google Scholar]
  4. Cooper D. A., Gatell J. M., Kroon S., Clumeck N., Millard J., Goebel F. D., Bruun J. N., Stingl G., Melville R. L., González-Lahoz J. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med. 1993 Jul 29;329(5):297–303. doi: 10.1056/NEJM199307293290501. [DOI] [PubMed] [Google Scholar]
  5. Davis T. M., White N. J., Looareesuwan S., Silamut K., Warrell D. A. Quinine pharmacokinetics in cerebral malaria: predicted plasma concentrations after rapid intravenous loading using a two-compartment model. Trans R Soc Trop Med Hyg. 1988;82(4):542–547. doi: 10.1016/0035-9203(88)90498-1. [DOI] [PubMed] [Google Scholar]
  6. Dollery C. T. The future of clinical pharmacology and therapeutics. Clin Pharmacol Ther. 1987 Jan;41(1):1–2. doi: 10.1038/clpt.1987.1. [DOI] [PubMed] [Google Scholar]
  7. Dyson E. H., Proudfoot A. T., Prescott L. F., Heyworth R. Death and blindness due to overdose of quinine. Br Med J (Clin Res Ed) 1985 Jul 6;291(6487):31–33. doi: 10.1136/bmj.291.6487.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Edwards G., Winstanley P. A., Ward S. A. Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations. Clin Pharmacokinet. 1994 Aug;27(2):150–165. doi: 10.2165/00003088-199427020-00006. [DOI] [PubMed] [Google Scholar]
  9. Fischl M. A., Parker C. B., Pettinelli C., Wulfsohn M., Hirsch M. S., Collier A. C., Antoniskis D., Ho M., Richman D. D., Fuchs E. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1990 Oct 11;323(15):1009–1014. doi: 10.1056/NEJM199010113231501. [DOI] [PubMed] [Google Scholar]
  10. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. doi: 10.1073/pnas.83.21.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Greene W. C. The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med. 1991 Jan 31;324(5):308–317. doi: 10.1056/NEJM199101313240506. [DOI] [PubMed] [Google Scholar]
  12. Hall E. T., Yan J. P., Melançon P., Kuchta R. D. 3'-Azido-3'-deoxythymidine potently inhibits protein glycosylation. A novel mechanism for AZT cytotoxicity. J Biol Chem. 1994 May 20;269(20):14355–14358. [PubMed] [Google Scholar]
  13. Ham C. Where now for the NHS reforms? BMJ. 1994 Aug 6;309(6951):351–352. doi: 10.1136/bmj.309.6951.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hao Z., Cooney D. A., Hartman N. R., Perno C. F., Fridland A., DeVico A. L., Sarngadharan M. G., Broder S., Johns D. G. Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol. 1988 Oct;34(4):431–435. [PubMed] [Google Scholar]
  15. Harrison A. C., Kitteringham N. R., Clarke J. B., Park B. K. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem Pharmacol. 1992 Apr 1;43(7):1421–1430. doi: 10.1016/0006-2952(92)90198-r. [DOI] [PubMed] [Google Scholar]
  16. Hatton C. S., Peto T. E., Bunch C., Pasvol G., Russell S. J., Singer C. R., Edwards G., Winstanley P. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet. 1986 Feb 22;1(8478):411–414. doi: 10.1016/s0140-6736(86)92371-8. [DOI] [PubMed] [Google Scholar]
  17. Hirsch M. S., D'Aquila R. T. Therapy for human immunodeficiency virus infection. N Engl J Med. 1993 Jun 10;328(23):1686–1695. doi: 10.1056/NEJM199306103282307. [DOI] [PubMed] [Google Scholar]
  18. Neftel K. A., Woodtly W., Schmid M., Frick P. G., Fehr J. Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 1986 Mar 15;292(6522):721–723. doi: 10.1136/bmj.292.6522.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. O'Neill P. M., Harrison A. C., Storr R. C., Hawley S. R., Ward S. A., Park B. K. The effect of fluorine substitution on the metabolism and antimalarial activity of amodiaquine. J Med Chem. 1994 Apr 29;37(9):1362–1370. doi: 10.1021/jm00035a017. [DOI] [PubMed] [Google Scholar]
  20. Park B. K., Pirmohamed M., Kitteringham N. R. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol. 1992 Nov;34(5):377–395. doi: 10.1111/j.1365-2125.1992.tb05647.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pirmohamed M., Kitteringham N. R., Park B. K. The role of active metabolites in drug toxicity. Drug Saf. 1994 Aug;11(2):114–144. doi: 10.2165/00002018-199411020-00006. [DOI] [PubMed] [Google Scholar]
  22. Sale M., Sheiner L. B., Volberding P., Blaschke T. F. Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther. 1993 Nov;54(5):556–566. doi: 10.1038/clpt.1993.188. [DOI] [PubMed] [Google Scholar]
  23. Samuels M. E., Koop C. E., Hartsock P. I. Single-use syringes. N Engl J Med. 1991 Apr 4;324(14):996–997. doi: 10.1056/NEJM199104043241415. [DOI] [PubMed] [Google Scholar]
  24. Shann F., Stace J., Edstein M. Pharmacokinetics of quinine in children. J Pediatr. 1985 Mar;106(3):506–510. doi: 10.1016/s0022-3476(85)80692-2. [DOI] [PubMed] [Google Scholar]
  25. Stretcher B. N., Pesce A. J., Frame P. T., Greenberg K. A., Stein D. S. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS. 1994 Jun;8(6):763–769. doi: 10.1097/00002030-199406000-00007. [DOI] [PubMed] [Google Scholar]
  26. Sykes R. Innovation in the pharmaceutical industry. BMJ. 1994 Aug 13;309(6952):422–423. doi: 10.1136/bmj.309.6952.422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Volberding P. A., Lagakos S. W., Grimes J. M., Stein D. S., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S., Phair J. P., Mitsuyasu R. T. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA. 1994 Aug 10;272(6):437–442. [PubMed] [Google Scholar]
  28. Winstanley P., Newton C., Watkins W., Mberu E., Ward S., Warn P., Mwangi I., Waruiru C., Pasvol G., Warrell D. Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: the importance of unbound quinine concentration. Trans R Soc Trop Med Hyg. 1993 Mar-Apr;87(2):201–206. doi: 10.1016/0035-9203(93)90494-b. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES